Remove Big Data Remove Clinical Development Remove Generic Pharmaceutical
article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

With Blackstone Life Sciences, up to €300 million (around $315 million USD) will be invested to accelerate pivotal studies and clinical development programs for formulating the subcutaneous delivery of the anti-CD38 antibody Sarclisa (isatuximab) for the treatment of multiple myeloma. Teva Pharmaceutical Industries Ltd.

Sales 96